T7 peptide -modified ZL006 long-circulating liposome and preparation method thereof

The invention discloses a T7 peptide-modified ZL006 long-circulating liposome which comprises phospholipid, cholesterol, methoxy-polyethylene glycol-phosphatidyl ethanolamine, T7 peptide-polyethylene glycol-phosphatidyl ethanolamine and therapeutically effective amount of ZL006. The invention also d...

Full description

Saved in:
Bibliographic Details
Main Authors WANG ZHONGYUAN, ZHAO YUE, WANG BAOYAN, WU LIN, XU QUNWEI, LYU LINGYAN, XIN HONGLIANG
Format Patent
LanguageChinese
English
Published 18.06.2014
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention discloses a T7 peptide-modified ZL006 long-circulating liposome which comprises phospholipid, cholesterol, methoxy-polyethylene glycol-phosphatidyl ethanolamine, T7 peptide-polyethylene glycol-phosphatidyl ethanolamine and therapeutically effective amount of ZL006. The invention also discloses a preparation method of the T7-modified ZL006 long-circulating liposome. According to the T7-modified ZL006 long-circulating liposome, the medicine ZL006 is encapsulated in a lipid bilayer, so that the circulating time of the medicine in the body is greatly prolonged; by means of T7 peptide modification, the blood brain barrier penetration capability of the medicine is improved, the medicine for treating cerebral apoplexy is effectively and concentratedly transferred to the cerebral apoplexy part, the treatment effect of the medicine is furthest exerted, and meanwhile, the toxic and side effects of the whole body are reduced.
Bibliography:Application Number: CN2014149462